Gilead doubles down on HIV prevention, treatment amid Covid setbacks and awaiting FDA decision on long-acting candidate

Amid predictions of HIV advances unraveling during Covid, Gilead Sciences is doubling down on prevention, treatment options and on-the-ground community efforts, even as it awaits an FDA decision on its long-acting candidate.